Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by scarlet1967on Feb 04, 2021 8:50pm
228 Views
Post# 32480406

Say the words instead of whispering

Say the words instead of whispering

Say loud and clear what your audience want to hear, show what they want to see, do what they want you to do and put yourself in their position to find out what they need to become your investors.
Hello Mr. x. we are happy to explain the prospects of our company so you understand it before making any decision as surly we do not want you to make any financial decisions not being fully informed and regret it later.
We are an R&D company with few promising pipe lines. We have an innovative oncology platform which recently got some how rare accelerated designation from FDA which is usually granted to drugs which are in the process of development for serious and unmet medical conditions also we feel this designation by the agency is an indication that they like the MOA of our program.
Our intention has always been to move faster than other companies in the industry and having the accelerated designation will enable us to achieve that, as we be able to send our findings to the agency and they will be responding fast to our results therefore the protocol can be finalized much sooner than usual due to faster communications.
The oncology program if successful can treat a numbe of cancers for instance breast cancer with the prevalence of x and market opportunities of $ and it also can treat cancer b with the prevalence of y and market opportunities of $ and etc etc, Therefore we are extremely excited not only to cure a lethal disease but also all these cancer treatments combined have a market opportunity of $$$$.
We are scheduled to start the trial on ... anc will potentially announce the first dosing on ...  we then will be able to potentially announce the early results on ...etc etc. 
We also are scheduled to start the phase 3 for a serious lethal condition called NASH with growing prevalence and no approved medication to date. We will be one of very few phase 3 companies in that industry with market opportunity $$.Our approache in that protocol is innovative when for more than a decade other approaches have failed therefore we believe our drug could be the first approved drug for NASH.
We also have two approved drugs with projected compounded growth of %25 percent in the next 4 years therefore we believe the sakes of our drugs will increase by more than %240 in that time period.
We have been invited to many conferences arranged by big institutions to present our company therefore we believe some of big pharmaceutical companies in the same industry are interested to collaborate with us but we will consider any potential partnership if the terms of the deal are favourable as we don't want to give away any part of our R&D programs since they all have the potential to be a extremely promising financial opportunities but at any given time we might consider that option.
Also feel free to do your own due diligence and look up the comparable companies and their current valuations.

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse